Plasma amyloid-β (Aβ) 42, phosphorylated tau (p-tau) 181, and neurofilament light chain
(NfL) are promising biomarkers of Alzheimer's disease (AD). However, whether these …

INTRODUCTION Plasma biomarkers are altered years prior to Alzheimer's disease (AD)
clinical onset. METHODS We measured longitudinal changes in plasma amyloid‐beta (Aβ) …

Abstract Introduction Blood‐based Alzheimer's disease (AD) biomarkers provide
opportunities for community studies and across ethnic groups. We investigated blood …

Background Previous studies reported the value of blood-based biomarkers in predicting
Alzheimer disease (AD) progression among individuals with different disease stages …

Introduction We studied usefulness of combining blood amyloid beta (Aβ) 42/Aβ40,
phosphorylated tau (p‐tau) 217, and neurofilament light (NfL) to detect abnormal brain Aβ …

Introduction Plasma amyloid beta (Aβ) 1‐42/Aβ1‐40 ratio, phosphorylated‐tau181 (p‐
tau181), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) are putative blood …

Aims There is increasing evidence that plasma biomarkers are specific biomarkers for
Alzheimer's disease (AD) pathology, but their potential utility in Obj‐SCD (objectively …

Background: Plasma-based biomarkers would be potential biomarkers for early diagnosis of
Alzheimer's disease (AD) because they are more available and cost-effective than …

Introduction Plasma biomarkers—cost effective, non‐invasive indicators of Alzheimer's
disease (AD) and related disorders (ADRD)—have largely been studied in clinical research …

Several promising plasma biomarkers for Alzheimer's disease have been recently
developed, but their neuropathological correlates have not yet been fully determined. To …